Compare AbCellera Biologics Inc (ABCL) vs Carlyle Group Inc (CG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Carlyle Group Inc — how do they compare? AbCellera Biologics Inc trades at $9.2 (market cap $2.99B), while Carlyle Group Inc trades at $48.27 (market cap $17.23B). The key difference: Carlyle Group Inc is far larger — about 5.8× AbCellera Biologics Inc's market cap, and Carlyle Group Inc pays a 2.9% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | CG | |
|---|---|---|
Market Cap | $2.99B | $17.23B |
Sector | Health | Financials |
52-Week High | $9.76 | $69.35 |
52-Week Low | $2.78 | $40.52 |
Enterprise Value | $2.58B | — |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CG trades at $47.80, up 0.02% daily, with a bullish technical signal from moving averages and a consensus analyst price target of $59.14. Recent Q2 2026 earnings beat expectations, with EPS of $1.07 versus $0.91 expected, while revenue trends show volatility, declining to $2.8B in 2026 from $3.2B in 2025. The company maintains a dividend of $0.35 per share and has strong institutional interest, with 53.84% of analysts rating it a Buy.
The outlook for CG is positive due to earnings beats and analyst optimism, but risks include inconsistent cash flow from operations and declining revenue. Investment opportunity lies in potential upside to the price target, supported by fundraising strength and strategic partnerships, though investors should monitor execution risks and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →
